Gao Lixiong, Huang Jinfeng, Cao Liqun, Rong Liyuan, Cui Bei, Zhang Xuekang, Shao Weiyang, Wang Fengxiang
Senior Department of Ophthalmology, The Third Medical Centre of Chinese People's Liberation Army General Hospital, No.69 Yongding Road, Haidian District, Beijing, China.
Department of Ophthalmology, The Sixth Medical Centre of Chinese People's Liberation Army General Hospital, No.6 Fucheng Road, Haidian District, Beijing, China.
BMC Ophthalmol. 2025 Jul 1;25(1):375. doi: 10.1186/s12886-025-04185-7.
This study aims to describe and evaluate the efficacy of transscleral peripheral retinal cryotherapy (TPRC) combined with other intraocular pressure (IOP)-lowering treatments in patients with open-angle neovascular glaucoma (NVG).
A retrospective observational case series was conducted, including 16 eyes from 16 patients with open-angle NVG, treated with combinations of TPRC and IOP-lowering eyedrops, TPRC and cyclocryotherapy, or TPRC and transscleral ciliary photocoagulation (TCP) over a 4-year period (01/2020-01/2024). Preoperative, intraoperative data, and postoperative data at day 1, week 1, and months 1, 6, and 12 were systematically collected.
The primary causes of NVG were proliferative diabetic retinopathy (68.75%) and central retinal vein occlusion (31.25%). The mean (± SD) pre-treatment IOP was 36.56 ± 6.73 mmHg, decreasing to 14.81 ± 2.59 mmHg at 12 months of follow-up. The mean (± SD) best-corrected visual acuity (BCVA) in LogMAR was 2.25 ± 0.8 at baseline, improving to 1.81 ± 0.50 at 12 months. All patients demonstrated a reduction in iris neovascularization following TPRC. No serious complications were observed.
TPRC-based IOP-lowering combination therapies appear to be an effective treatment option for open-angle NVG. These approaches may be particularly suitable for primary healthcare settings, hospitals without advanced glaucoma surgery capabilities, or NVG patients with limited economic resources and extremely elevated IOP.
本研究旨在描述和评估经巩膜周边视网膜冷冻疗法（TPRC）联合其他降低眼压（IOP）治疗方法对开角型新生血管性青光眼（NVG）患者的疗效。
进行了一项回顾性观察病例系列研究，纳入16例开角型NVG患者的16只眼，在4年期间（2020年1月至2024年1月）接受了TPRC与降眼压眼药水联合治疗、TPRC与睫状体冷冻疗法联合治疗或TPRC与经巩膜睫状体光凝术（TCP）联合治疗。系统收集术前、术中数据以及术后第1天、第1周、第1个月、第6个月和第12个月的数据。
NVG的主要病因是增殖性糖尿病视网膜病变（68.75%）和视网膜中央静脉阻塞（31.25%）。治疗前平均（±标准差）眼压为36.56±6.73 mmHg，随访12个月时降至14.81±2.59 mmHg。基线时平均（±标准差）最佳矫正视力（BCVA）的LogMAR值为2.25±0.8，12个月时改善至1.81±0.50。所有患者在TPRC后虹膜新生血管均减少。未观察到严重并发症。
基于TPRC的降眼压联合治疗似乎是开角型NVG的有效治疗选择。这些方法可能特别适用于基层医疗环境、没有先进青光眼手术能力的医院或经济资源有限且眼压极高的NVG患者。
